Biosimilars in inflammatory bowel disease: Ready for prime time?

Current Opinion in Gastroenterology

Volumn 31, Issue 4, 2015, Pages 290-295

  Gomollón, Fernando ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

Author keywords

Biologic; Biosimilar; Crohn's disease; CT P13; Inflammatory bowel disease; Infliximab; Ulcerative colitis

Indexed keywords

BIOSIMILAR AGENT; GASTROINTESTINAL AGENT; INFLIXIMAB;

ARTICLE; CLINICAL TRIAL (TOPIC); HUMAN; INFLAMMATORY BOWEL DISEASE; PRACTICE GUIDELINE; PROFIT; RANDOMIZED CONTROLLED TRIAL (TOPIC); DRUG CONTROL; DRUG COST; DRUG SUBSTITUTION; ECONOMICS; HEALTH PERSONNEL ATTITUDE; INFLAMMATORY BOWEL DISEASES; PROCEDURES; STATISTICS AND NUMERICAL DATA;

ATTITUDE OF HEALTH PERSONNEL; BIOSIMILAR PHARMACEUTICALS; DRUG AND NARCOTIC CONTROL; DRUG COSTS; DRUG SUBSTITUTION; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATORY BOWEL DISEASES; INFLIXIMAB;

EID: 84941549073     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0000000000000184     Document Type: Article

References (77)

1. Plitnick LM, Herzyk DJ, editors. Nonclinical development of novel biologics, biosimilars, vaccines and specialty biologics. Academic Press; 2013.
2. Patek SN. Materials science. Biomimetics and evolution. Science 2014;345:1448-1449.
3. Alkan SS. Monoclonal antibodies: the story of a discovery that revolutionized science and medicine. Nat Rev Immunol 2004;4:153-156.
4. Danese S, Colombel JF, Reinisch W, Rutgeerts PJ. Review article: infliximab for Crohn's disease treatment - shifting therapeutic strategies after 10 years of clinical experience. Aliment Pharmacol Ther 2011;33:857-869.
5. D'Haens GR, Sartor RB, Silverberg MS, et al. Future directions in inflammatory bowel disease management. J Crohns Colitis 2014;8:726-734.
6. Greene JA. Generic: the unbranding of modern medicine. Baltimore: John Hopkins University Press; 2014.
7. Grabowski H, Guha R, Salgado M. Biosimilar competition: lessons from Europe. Nat Rev Drug Discov 2014;13:99-100.
8. McCamish M, Woollett G. The state of the art in the development of biosimilars. Clin Pharmacol Ther 2012;91:405-417.
9. Rinaudo-Gaujous M, Paul S, Tedesco ED, et al. Review article: biosimilars are the next generation of drugs for liver and gastrointestinal diseases. Aliment Pharmacol Ther 2013;38:914-924.
10. Beck A, Reichert JM. Approval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industry. MAbs 2013;5:621-623.
11. Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis 2013;72:1605-1612.
12. Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 2013;72:1613-1620.
13. Gomollon F. Biosimilars: are they bioequivalent? Dig Dis 2014;32(Suppl 1):82-87.
14. Ahmed I, Kaspar B, Sharma U. Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States. Clin Ther 2012;34:400-419.
15. Ledford H. First biosimilar drug set to enter US market. Nature 2015;517:253-254.
16. Walsh G. Biopharmaceutical benchmarks 2014. Nat Biotechnol 2014;32:992-1000.
17. Gecse KB, Khanna R, Van Den Brink GR, et al. Biosimilars in IBD: hope or expectation? Gut 2013;62:803-807.
18. ••] can be chosen by the busy clinician).
19. Weise M, Bielsky MC, De Smet K, et al. Biosimilars: what clinicians should know. Blood 2012;120:5111-5117.
20. Fiorino G, Danese S. The biosimilar road in inflammatory bowel disease: the right way? Best Pract Res Clin Gastroenterol 2014;28:465-471.
21. Miletich J, Eich G, Grampp G, Mounho B. Biosimilars 2.0: guiding principles for a global 'patients first' standard. MAbs 2011;3:318-325.
22. Dorner T, Strand V, Castaneda-Hernandez G, et al. The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis 2013;72:322-328.
23. Ebbers HC, Crow SA, Vulto AG, Schellekens H. Interchangeability, immunogenicity and biosimilars. Nat Biotechnol 2012;30:1186-1190.
24. Weise M, Bielsky MC, De Smet K, et al. Biosimilars - why terminology matters. Nat Biotechnol 2011;29:690-693.
25. Felix T, Johansson TT, Colliatie JA, et al. Biologic product identification and US pharmacovigilance in the biosimilars era. Nat Biotechnol 2014;32:128-130.
26. Mendes De Abreu M, Strand V, Levy RA, Araujo DV. Putting the value into biosimilar decision making: the judgment value criteria. Autoimmun Rev 2014;13:678-684.
27. Blackstone EA, Fuhr JP Jr. Innovation and competition: will biosimilars succeed? The creation of an FDA approval pathway for biosimilars is complex and fraught with hazard. Yes, innovation and market competition are at stake. But so are efficacy and patient safety. Biotechnol Healthc 2012;9:24-27.
28. Van Der Valk ME, Mangen MJ, Leenders M, et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFalpha therapy: results from the COIN study. Gut 2014;63:72-79. Excellent study that shows clearly the changes in costs in IBD during the recent years and the key role of biologics in developed areas.
29. Burisch J, Vardi H, Pedersen N, et al. Costs and resource utilization for diagnosis and treatment during the initial year in a European inflammatory bowel disease inception cohort: an ECCO-EpiCom Study. Inflamm Bowel Dis 2015;21:121-131. Population-based study that confirms that biologics represent an important part of the cost even in the first year after diagnosis.
30. Tang DH, Harrington AR, Lee JK, et al. A systematic review of economic studies on biological agents used to treat Crohn's disease. Inflamm Bowel Dis 2013;19:2673-2694.
31. Roblin X, Danese S, Peyrin-Biroulet L. Does anti-TNF therapy cost so many COINs? Gastroenterology 2014;146:309-311.
32. Wang W, Manmohan S. Biological drug products: development and strategies. Hoboken, NJ: John Wiley & Sons; 2014.
33. Berggren R, Moller M, Moss R, et al. Outlook for the next 5 years in drug innovation. Nat Rev Drug Discov 2012;11:435-436.
34. Beck A. Biosimilar, biobetter and next generation therapeutic antibodies. MAbs 2011;3:107-110.
35. Blackstone EA, Joseph PF. The economics of biosimilars. Am Health Drug Benefits 2013;6:469-478.
36. Farfan-Portet MI, Gerkens S, Lepage-Nefkens I, et al. Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures? Eur J Health Econ 2014;15:223-228.
37. Danese S, Fiorino G, Michetti P. Viewpoint: knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization. J Crohns Colitis 2014;8:1548-1550. A simple study, but very informative about the current opinions and knowledge about biosimilars in European IBD clinicians, a must-read for planning educative activities on the topic.
38. Grabowski D, Henderson B, Lam D, et al. Attitudes towards subsequent entry biologics/biosimilars: a survey of Canadian rheumatologists. Clin Rheumatol 2015. [Epub ahead of print]
39. Danese S, Gomollon F, Governing B. Operational Board of E. ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). J Crohns Colitis 2013;7:586-589.
40. Arguelles-Arias F, Barreiro-De-Acosta M, Carballo F, et al. Joint position statement by 'Sociedad Espanola de Patologia Digestiva' (Spanish Society of Gastroenterology) and 'Sociedad Espanola de Farmacologia' (Spanish Society of Pharmacology) on biosimilar therapy for inflammatory bowel disease. Rev Esp Enferm Dig 2013;105:37-43.
41. Arguelles-Arias F, Barreiro-De-Acosta M, Carballo F, et al. New contributions to consensus on biosimilars. Rev Esp Enferm Dig 2014;106:228-229.
42. Devlin SM, Bressler B, Bernstein CN, et al. Overview of subsequent entry biologics for the management of inflammatory bowel disease and Canadian Association of Gastroenterology position statement on subsequent entry biologics. Can J Gastroenterol 2013;27:567-571.
43. Annese V, Vecchi M; Italian Group for the Study of IBD. Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease. Dig Liver Dis 2014;46:963-968.
44. Fiorino G, Girolomoni G, Lapadula G, et al. The use of biosimilars in immunemediated disease: a joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper. Autoimmun Rev 2014;13:751-755.
45. Kurki P, Bielsky MC; Working Party on Similar Biological Medicinal Products of Committee for Medicinal Products for Human U. ECCO position challenged by European drug regulators. J Crohns Colitis 2014;8:258.
46. Danese S, Gomollon F, Michetti P. EMA response to ECCO position statement on biosimilars. J Crohns Colitis 2014;8:259.
47. Castaneda-Hernandez G, Szekanecz Z, Mysler E, et al. Biopharmaceuticals for rheumatic diseases in Latin America, Europe, Russia, and India: innovators, biosimilars, and intended copies. Joint Bone Spine 2014;81:471-477.
48. Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 2010;10:301-316.
49. Berkowitz SA, Engen JR, Mazzeo JR, Jones GB. Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars. Nat Rev Drug Discov 2012;11:527-540.
50. Warren JB. Generics, chemisimilars and biosimilars: is clinical testing fit for purpose? Br J Clin Pharmacol 2013;75:7-14.
51. McCamish M, Woollett G. The continuum of comparability extends to biosimilarity: how much is enough and what clinical data are necessary? Clin Pharmacol Ther 2013;93:315-317.
52. Schneider CK, Borg JJ, Ehmann F, et al. In support of the European Union biosimilar framework. Nat Biotechnol 2012;30:745-748.
53. Ebbers HC. Biosimilars: in support of extrapolation of indications. J Crohns Colitis 2014;8:431-435.
54. Schiestl M, Stangler T, Torella C, et al. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol 2011;29:310-312.
55. Weise M, Kurki P, Wolff-Holz E, et al. Biosimilars: the science of extrapolation. Blood 2014;124:3191-3196. A detailed description of the scientific rationale of extrapolation. Should be read by clinicians interested in the topic.
56. Calvo B, Zuniga L. EU's new pharmacovigilance legislation: considerations for biosimilars. Drug Saf 2014;37:9-18.
57. Lee H. Is extrapolation of the safety and efficacy data in one indication to another appropriate for biosimilars? AAPS J 2014;16:22-26.
58. Schellekens H, Moors E. Biosimilars or semi-similars? Nat Biotechnol 2015;33:19-20.
59. Schellekens H, Moors E. Clinical comparability and European biosimilar regulations. Nat Biotechnol 2010;28:28-31.
60. Scott BJ, Klein AV, Wang J. Biosimilar monoclonal antibodies: a Canadian regulatory perspective on the assessment of clinically relevant differences and indication extrapolation. J Clin Pharmacol 2014;55(Suppl 3):S123-S132.
61. Feagan BG, Choquette D, Ghosh S, et al. The challenge of indication extrapolation for infliximab biosimilars. Biologicals 2014;42:177-183. A very detailed and well-referenced review with the arguments against extrapolation. Should also be read for a balanced critical opinion.
62. Guilliams M, Bruhns P, Saeys Y, et al. The function of Fcgamma receptors in dendritic cells and macrophages. Nat Rev Immunol 2014;14:94-108.
63. Ordas I, Mould DR, Feagan BG, Sandborn WJ. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther 2012;91:635-646.
64. Tam SH, McCarthy SG, Brosnan K, et al. Correlations between pharmacokinetics of IgG antibodies in primates vs. FcRn-transgenic mice reveal a rodent model with predictive capabilities. MAbs 2013;5:397-405.
65. Kaser A. Not all monoclonals are created equal - lessons from failed drug trials in Crohn's disease. Best Pract Res Clin Gastroenterol 2014;28:437-449.
66. Zhang A, Tzeng JY, Chow SC. Statistical considerations in biosimilar assessment using biosimilarity index. J Bioequiv Availab 2013;5:209-214.
67. Thelwell C, Longstaff C. Biosimilars: the process is the product. The example of recombinant streptokinase. J Thromb Haemost 2014;12:1229-1233.
68. De Witt EM, Brunner HI. The landscape of comparative effectiveness research in rheumatology. Nat Rev Rheumatol 2014;10:57-62.
69. Beck A, Wurch T, Bailly C, Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 2010;10:345-352.
70. Beck A, Reichert JM. Marketing approval of mogamulizumab: a triumph for glyco-engineering. MAbs 2012;4:419-425.
71. Mullard A. Can next-generation antibodies offset biosimilar competition? Nat Rev Drug Discov 2012;11:426-428.
72. Sathish JG, Sethu S, Bielsky MC, et al. Challenges and approaches for the development of safer immunomodulatory biologics. Nat Rev Drug Discov 2013;12:306-324.
73. Ueda T. Next-generation optimized biotherapeutics - a review and preclinical study. Biochim Biophys Acta 2014;1844:2053-2057. Some good ideas for the future.
74. Emecen-Huja P, Hasan I, Miller CS. Biologic markers of failing implants. Dent Clin North Am 2015;59:179-194.
75. Dalziel M, Crispin M, Scanlan CN, et al. Emerging principles for the therapeutic exploitation of glycosylation. Science 2014;343:1235681.
76. Wang P, Dong S, Shieh JH, et al. Erythropoietin derived by chemical synthesis. Science 2013;342:1357-1360.
77. Hsieh-Wilson LC, Griffin ME. Chemistry. Improving biologic drugs via total chemical synthesis. Science 2013;342:1332-1333.